Review

Archivum Immunologiae et Therapiae Experimentalis

, Volume 57, Issue 3, pp 189-198

Dendritic cell-based cancer immunotherapies

  • Shin-ichiro FujiiAffiliated withResearch Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama RIKEN Email author 
  • , Takuya TakayamaAffiliated withDivision of Cancer Genomics, Cancer Institute (Japanese Foundation for Cancer Research)
  • , Miki AsakuraAffiliated withResearch Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama RIKEN
  • , Kaori AkiAffiliated withResearch Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama RIKEN
  • , Koji FujimotoAffiliated withNTT West Kyushu Hospital, Kumamoto
  • , Kanako ShimizuAffiliated withResearch Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama RIKENResearch Unit for Therapeutic Model, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Because of their unique role in linking the innate and adaptive immune systems, dendritic cells (DCs) have been a logical focus for novel immunotherapies. However, strategies employing active immunization with ex vivo generated and antigen–pulsed DCs have shown limited efficacy in clinical trials. These past approaches did not take into account the complex interactions between cells of the innate immune system and DCs during DC maturation, antigen processing, and presentation to naïve T cells. By better understanding the natural sequence of events occurring in vivo during an effective immune response, we can tailor antitumor immunotherapeutic strategies to augment aspects of this response from the activation of innate immune cells to antigen uptake and DC maturation to priming of naïve T cells and, ultimately, to the establishment of antitumor immunity. Current DC vaccination strategies utilize a number of methods to recapitulate the cascade of events that culminate in a protective antitumor immune response.

Keywords

dendritic cells (DCs) adjuvant ex vivo DC therapy in vivo DC therapy immunotherapy